Lista de obras - Angelica Loskog - Dominio Público Uruguay

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

artículo científico publicado en 2018

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

artículo científico publicado en 2016

AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model

artículo científico publicado en 2005

AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.

artículo científico publicado en 2010

AdCD40L—Crossing the Valley of Death? ⬇️

artículo científico publicado el 1 de agosto de 2012

Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment

artículo científico publicado en 2004

Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.

artículo científico publicado en 2006

Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro

artículo científico publicado en 2011

CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery.

artículo científico publicado en 2012

CD40L - a multipotent molecule for tumor therapy.

artículo científico publicado en 2007

CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes

artículo científico publicado en 2014

Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects

artículo científico publicado en 2009

CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.

artículo científico publicado en 2005

Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma

artículo científico publicado en 2008

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy

artículo científico publicado en 2010

Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients

scientific article published on 02 December 2019

Genetically engineered T cells for the treatment of cancer ⬇️

artículo científico publicado el 1 de febrero de 2013

Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines

artículo científico publicado en 2007

IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1

artículo científico publicado en 2019

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40

scientific article published on 01 May 2020

In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.

artículo científico publicado en 2002

Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia

artículo científico publicado en 2013

Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition

artículo científico publicado en 2009

Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue.

artículo científico publicado en 2009

Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy.

artículo científico publicado en 2005

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

scientific article published on 03 March 2020

T regulatory cells in B‐cell malignancy – tumour support or kiss of death? ⬇️

artículo científico publicado el 1 de abril de 2012

T regulatory cells lacking CD25 are increased in MS during relapse.

artículo científico publicado en 2010

T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.

artículo científico publicado en 2013

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4 ⬇️

artículo científico publicado el 10 de noviembre de 2011

The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation

artículo científico publicado en 2017

The immunotherapy of prostate and bladder cancer.

artículo científico publicado en 2005

αB-Crystallin regulates expansion of CD11b⁺Gr-1⁺ immature myeloid cells during tumor progression.

artículo científico publicado en 2012

Lista de obras de Angelica Loskog

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model

AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.

AdCD40L—Crossing the Valley of Death? ⬇️

Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment

Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.

Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro

CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery.

CD40L - a multipotent molecule for tumor therapy.

CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes

Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects

CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.

Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy

Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients

Genetically engineered T cells for the treatment of cancer ⬇️

Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines

IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40

In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.

Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia

Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition

Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue.

Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy.

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

T regulatory cells in B‐cell malignancy – tumour support or kiss of death? ⬇️

T regulatory cells lacking CD25 are increased in MS during relapse.

T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4 ⬇️

The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation

The immunotherapy of prostate and bladder cancer.

αB-Crystallin regulates expansion of CD11b⁺Gr-1⁺ immature myeloid cells during tumor progression.